Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Feature|Videos|August 13, 2025
Advances across urology: Insights from UNC faculty
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Urologists from the University of North Carolina share insights into key advancements across the field of urologic oncology.
Advertisement
The field of urologic oncology is rapidly evolving. Urology Times® recently spoke with several urologists from the University of North Carolina, who shared insights into key advancements across the field.
Specifically, you'll hear from:
- Marc A. Bjurlin, DO, MSc, FACOS on the evolving role of mpMRI
- Kathryn H. Gessner, MD, PhD on the growing applications for genomic testing
- Mary Beth Westerman, MD on the amendment to microhematuria guideline
- Zachary Feuer, MD on a rapid access program for elevated PSA
Advertisement
Related to this article
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
Advertisement
Advertisement